HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy

This publication has 25 references indexed in Scilit:

• Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.
  Proceedings of the National Academy of Sciences, 1992
• The Safety and Efficacy of Zidovudine (AZT) in the Treatment of Subjects with Mildly Symptomatic Human Immunodeficiency Virus Type 1 (HIV) Infection
  Annals of Internal Medicine, 1990
• Plasma Viremia in Human Immunodeficiency Virus Infection
  New England Journal of Medicine, 1989
• Quantitation of Human Immunodeficiency Virus Type 1 in the Blood of Infected Persons
  New England Journal of Medicine, 1989
• HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy
  Science, 1989
• The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
  New England Journal of Medicine, 1987
• Development of Antiretroviral Therapy for the Acquired Immunodeficiency Syndrome and Related Disorders
  New England Journal of Medicine, 1987
• Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.
  Proceedings of the National Academy of Sciences, 1986
• ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX
  The Lancet, 1986
• 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.
  Proceedings of the National Academy of Sciences, 1985